Deal or Case news
Xenikos B.V., a clinical-stage biopharmaceutical company currently developing a novel therapy for treating immune related disorders, announced today the closing of EUR 40M in convertible debt consisting of two equal tranches of EUR 20M.

The financing was led by Veloxis Pharmaceuticals, Inc., with participation from existing investors, Medicxi, RA Capital Management, Oost NL and Sanquinnovate. In connection with the financing, Veloxis will obtain two sequential call options, each becoming active upon the release of its associated tranche, which provides Veloxis the exclusive option to exercise its right to acquire all of Xenikos’ outstanding shares.

Xenikos will use the proceeds of the financing to initiate a registrational Phase 3 clinical trial in the US and EU, which is designed to evaluate the efficacy and safety of their flagship product T-Guard® for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD) in patients following allogeneic stem cell transplantation versus ruxolitinib.

NautaDutilh's deal team consisted of Sybren de Beurs, Jeanine Evertse, Frans Ruijs (Corporate M&A), Florine Kuiperi (Corporate M&A notarial), Nina Kielman and Ash Beesemer (Tax).

Goodwin Procter LLP acted as US counsel to Xenikos.

Press release Xenikos

Related articles

Cookie notification

This functionality uses third-party cookies. Change your cookie preferences to view this content or view more information.
These cookies ensure that the website works properly. These cookies cannot be disabled.
These cookies can be placed by third parties, such as YouTube or Vimeo.
By deactivating categories, it is possible that related functionalities within the website may no longer work properly. It is always possible to change your preferences at a later time. View more information.